- Shares of Questcor Pharmaceuticals (QCOR) open lower by 2%.
- Over the weekend, Barron's — long skeptical of QCOR — questioned the relationship between the company and the Chronic Disease Fund.
- Bill Alpert asks whether the the two are "too close for comfort" and says the charity's help with co-pays is a major reason QCOR has been able to help patients obtain Acthar.
- "The co-pay arrangement with the CDF carries its own risk," Alpert writes, adding that "eight of the 37 disease states for which the CDF Website says it is enrolling patients are diseases for which Acthar is the only drug on the charity's list of approved therapies—even though branded and generic alternatives for those diseases are on the market."
at Zacks.com (Nov 17, 2014)